At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 54 enrolled
Drug / intervention
Lamotrigine +1 moredrug
Likely dose
Lamotrigine 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Reversing Corticosteroid Induced Memory Impairment
University of Texas Southwestern Medical Center·interventional·Posted Jun 11, 2010·Updated Aug 27, 2018
In Brief
A Phase 4 clinical trial evaluating Lamotrigine and Placebo for Memory Impairment. Completed, enrolled 54 participants across 1 site.
Detailed Summary
Medically stable outpatients receiving chronic oral corticosteroid therapy were enrolled in a 48-week randomized, double-blind, placebo-controlled, parallel-group, trial of lamotrigine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMemory Impairment
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedJun 2010
Primary CompletionJun 2015
TodayJul 2026
First PostedJun 11, 2010
Enrollment StartJun 1, 2010
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 16.1 years ago
Interventions
Lamotriginedrug
Lamotrigine will be initiated at 25 mg/day and upwardly titrated to a dose of 400 mg/day over 10 weeks.
Placebodrug